IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
1.890
+0.052 (2.83%)
Oct 13, 2026, 1:39 PM CET
IRLAB Therapeutics AB Earnings Call Transcripts
Fiscal Year 2024
-
The company is advancing a robust pipeline for Parkinson's and CNS disorders, leveraging a proprietary AI-driven platform for higher success rates and lower costs. Lead assets are progressing toward late-stage trials, with active partnering and financing efforts underway.